Insider Trading History of Dillaha Larry

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) by Dillaha Larry since 2007. The trader's CIK number is 1360463. At the time of the last reporting, Dillaha Larry was the EVP & Chief Medical of Insys Therapeutics, Inc.. (stock ticker symbol INSY). Also see all insider trading activities at Insys Therapeutics, Inc..

Note that in the past Dillaha Larry also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at First Horizon Pharmaceutical Corp (SCRX) by Dillaha Larry

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2008 SCRX 0 $0 2,538 $54,114 0 $0
2007 SCRX 0 $0 7,751 $196,634 0 $0

Yearly summary of insider trading at Insys Therapeutics, Inc. (INSY) by Dillaha Larry

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2014 INSY 0 $0 149,932 $11,962,924 149,932 $812,631


Insider trading activities at 2 companies by Dillaha Larry:

1. First Horizon Pharmaceutical Corp (SCRX)

2. Insys Therapeutics, Inc. (INSY)

Table 1. Insider trading of First Horizon Pharmaceutical Corp (SCRX) by Dillaha Larry

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2008-08-11 SCRX Sale 875 20.34 17,794
2008-04-25 SCRX Sale 350 19.35 6,772
2008-02-20 SCRX Sale 875 22.54 19,722
2008-01-23 SCRX Sale 438 22.44 9,826
2007-12-07 SCRX Sale 2,563 22.75 58,308
2007-10-10 SCRX Sale 3,500 28.00 98,000
2007-02-21 SCRX Sale 1,688 23.89 40,326

Table 2. Insider trading of Insys Therapeutics, Inc. (INSY) by Dillaha Larry

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2014-03-05 INSY Sale 149,932 79.79 11,962,924
2014-03-05 INSY Option Ex 149,932 5.42 812,631

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Dillaha Larry (EVP & Chief Medical of Insys Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.